Jnk1 Controls Mast Cell Degranulation and Il-1 Beta Production in Inflammatory Arthritis

Monica Guma,Jun-ichi Kashiwakura,Brian Crain,Yuko Kawakami,Bruce Beutler,Gary S. Firestein,Toshiaki Kawakami,Michael Karin,Maripat Corr
DOI: https://doi.org/10.1073/pnas.1016401107
2010-01-01
Abstract:Rheumatoid arthritis (RA) is a chronic inflammatory disease marked by bone and cartilage destruction. Current biologic therapies are beneficial in only a portion of patients; hence small molecules targeting key pathogenic signaling cascades represent alternative therapeutic strategies. Here we show that c-Jun N-terminal kinase (JNK) 1, but not JNK2, is critical for joint swelling and destruction in a serum transfer model of arthritis. The proinflammatory function of JNK1 requires bone marrow-derived cells, particularly mast cells. Without JNK1, mast cells fail to degranulate efficiently and release less IL-1β after stimulation via Fcγ receptors (FcγRs). Pharmacologic JNK inhibition effectively prevents arthritis onset and abrogates joint swelling in established disease. Hence, JNK1 controls mast cell degranulation and FcγR-triggered IL-1β production, in addition to regulating cytokine and matrix metalloproteinase biosynthesis, and is an attractive therapeutic target in inflammatory arthritis.
What problem does this paper attempt to address?